Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (171-180 of 282) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Urologic Oncology|August 16, 2022
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinomaPatrick K Tamukong, Paige Kuhlmann, Sungyong You, et al.
JCO Precision Oncology|February 8, 2023
Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR StudyEddy S Yang, Susan Halabi, Michael Rothe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-<i>β</i>2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancerRyan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
BMC Genomics|May 14, 2024
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
The Prostate|March 14, 2022
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancerTian Zhang, Julie Kephart, Elizabeth Bronson, et al.
JCI Insight|August 29, 2024
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomesHannah E Bergom, Ella Boytim, Sean McSweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
Pageof 29

Showing results (171-180 of 282) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Urologic Oncology|August 16, 2022
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinomaPatrick K Tamukong, Paige Kuhlmann, Sungyong You, et al.
JCO Precision Oncology|February 8, 2023
Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR StudyEddy S Yang, Susan Halabi, Michael Rothe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-<i>β</i>2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancerRyan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
BMC Genomics|May 14, 2024
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)Julia C F Quintanilha, Alexander B Sibley, Yingmiao Liu, et al.
The Prostate|March 14, 2022
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancerTian Zhang, Julie Kephart, Elizabeth Bronson, et al.
JCI Insight|August 29, 2024
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomesHannah E Bergom, Ella Boytim, Sean McSweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
Pageof 29